Diapedesis of leukocytes: Antisense oligonucleotides for rescue

Experimental Nephrology

Volumn 7, Issue 2, 1999, Pages 185-192

  Dragun, Duska ^a   Haller, Hermann ^a,b  

^a HUMBOLDT UNIVERSITY   (Germany)

^b FRANZ VOLHARD CLINIC   (Germany)

Author keywords

Acute renal failure; Adhesion molecules; Delayed graft function; Endothelium

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1;

CELL ADHESION; CELL INTERACTION; DRUG EFFECT; HUMAN; KIDNEY FAILURE; KIDNEY GRAFT; KIDNEY ISCHEMIA; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW;

EID: 0032945977     PISSN: 10187782     EISSN: None     Source Type: Journal    
DOI: 10.1159/000020599     Document Type: Review

References (68)

1. Pantoni L, Sarti C, Inzitar D: Cytokines and cell adhesion molecules in cerebral ischemia. Arterioscler Thromb Vasc Biol 1998;18:503-513.
2. Granger D. Cell adhesion and migration. II. Leukocyte-endothelial cell adhesion in the digestive system. Am J Physiol 1997;36:G982-G986.
3. Rabb H, O'Meara YM, Maderna P, Coleman P, Brady HR: Leukocytes, cell adhesion molecules and ischemic acute renal failure. Kidney Int 1997;51:1463-1468.
4. Granger DN, Korthuis RJ: Physiologic mechanisms of postischemic tissue injury. Annu Rev Physiol 1995;57:311-332.
5. Springer T: Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm. Cell 1994;76:301-314.
6. Pinsky D, Naka Y, Liao H, Oz MC, Wagner DD, Mayadas TN, Johnson RC, Hynes RO, Heath M, Lawson CA, Stern DM: Hypoxia-induced exocytosis of endothelial cell Weibel-Palade bodies. J Clin Invest 1996;97:493-500.
7. Del Pozo M, Sanchez-Mateos P, Sanchez-Madrid F: Cellular polarization induced by chemokines: A mechanism for leukocyte recruitment? Immunol Today 1996;17:127-131.
8. Del Maschio A, Zanetti A, Corada M, Rival Y, Ruco L, Lampugnani MG, Dejana E: Polymorphonuclear leukocyte adhesion triggers the disorganization of endothelial cell-to-cell adherens junctions. J Cell Biol 1996;135:497-510.
9. Weiss S: Tissue destruction by neutrophils. N Engl J Med 1989;320:365-376.
10. Inauen W, Granger DN, Meininger CJ, Schelling ME, Granger HJ, Kvietys PR: An in vitro model of ischemia/reperfusion-induced microvascular injury. Am J Physiol 1990;259:G134-G139.
11. Granger DN, Kubes P: The microcirculation and inflammation: Modulation of leukocyte-endothelial cell adhesion. J Leukoc Biol 1994; 55:662-675.
12. Bratt J, Palmblad J: Cytokine-induced neutrophil-mediated injury of human endothelial cells. J Immunol 1997;159:912-918.
13. Worthen G, Schwab B, Elson EL, Downey GP: Cellular mechanisms of stimulated neutrophils: Stiffening of cells induces retention in pores in vitro and lung capillaries in vivo. Science 1989;245:183-186.
14. Jerome S, Dore M, Paulson JC, Smith CV, Korthius RJ: P-selectin and ICAM-1 dependent adherence reactions: Role in the genesis of postischemic no-reflow. Am J Physiol 1994; 266:H1316-1321.
15. Bonventre J: Mechanisms of ischemic acute renal failure. Kidney Int 1993;43:1160-1178.
16. Wertheimer S, Myers CL, Wallace RW, Parks TP: Intercellular adhesion molecule-1 gene expression in human endothelial cells. J Biol Chem 1992;267:12030-12035.
17. Ledebur H, Parks TP: Transcriptional regulation of the intercellular adhesion molecule-1 gene by inflammatory cytokines in human endothelial cells. J Biol Chem 1995;270:933-943.
18. Chiang M, Chan H, Zounes MA, Freier SM, Lima WF, Bennett CF: Antisense oligonucleolides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J Biol Chem 1991;266:18162-18171.
19. Bennett CF, Condon TP, Grimm S, Chan H, Chiang MY: Inhibition of endothelial cell adhesion molecule expression with antisense oligonucleotides. J Immunol 1994;152:3530-3540.
20. Baker B, Lot SS, Condon TP, Cheng-Flournoy S, Lesnik EA, Sasmor HM, Bennett CF: 2′-O-(-methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. J Biol Chem 1997;272: 11994-12000.
21. Rothlein R, Dustin ML, Marlin SD, Springer TA: A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1. J Immunol 1986;137:1270-1274.
22. Staunton D, Marlin SD, Stratowa C, Dustin ML, Springer TA: Primary structure of ICAM-1 demonstrates interaction between members of immunolobulin and integrin superfamily. Cell 1988;52:925-933.
23. Voraberger G, Schäfer R, Stratowa C: Cloning of the human gene for intercellular adhesion molecule 1 and analysis of its 5-regulatory region. J Immunol 1991;147:2777-2786.
24. Kita Y, Takashi T, Iigo Y, Tamatani T, Miyasaka M, Horiuchi K: Sequence and expression of rat ICAM-1. Biochim Biophys Acta 1992; 1131:108-110.
25. Marlin SD, Springer TA: Purified intercellular molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1). Cell 1987;51:813-819.
26. Diamond M, Staunton DE, Marlin SD, Springer TA: Binding of the integrin Mac-1 (CD11b/CD18) to the third immunoglobulin-like domain of ICAM-1 (CD54) and its regulation by glycosylation. Cell 1991;65:961-971.
27. Languino L, Duperray A, Joganic KJ, Fornaro M, Thornton GB: Regulation of leukocyte-endothelium interaction and leukocyte transendothelial migration by intercellular adhesion molecule-1-fibrinogen recognition. Proc Natl Acad Sci USA 1995;92:1505-1509.
28. McCourt P, Ek B, Forsberg N, Gustafson S: Intercellular adhesion molecule-1 is a cell surface receptor for hyaluronan. J Biol Chem 1994;269:30081-30084.
29. Staunton D, Merluzzi VJ, Rothlein R, Barton R, Marlin SD, Springer TA: A cell adhesion molecule, ICAM-1, is the major surface receptor for rhinoviruses. Cell 1989;56:849-853.
30. Ockenhouse C, Betagari R, Springer TA, Staunton DE: Plasmodium falciparum-infected erythrocytes bind ICAM-1 at a site distinct from LFA-1, Mac-1, and human rhinovirus. Cell 1992;68:63-69.
31. Staunton D, Dustin ML, Erickson HP, Springer TA: The arrangement of the immunoglobulin-like domains of ICAM-1 and the binding sites for LFA-1 and rhinovirus. Cell 1990; 61:243-254.
32. van de Stolpe A, van der Saag PT: Intercellular adhesion molecule-1. J Mol Med 1996:74:13-33.
33. Bevilacqua M, Nelson RM, Mannori G, Cecconi, O: Endothelial-leukocyte adhesion molecules in human disease. Annu Rev Med 1994; 45:361-378.
34. Albelda S, Smith CW, Ward PA: Adhesion molecules and inflammatory injury. FASEB J 1994;8:504-512.
35. Gerritsen M, Bloor CM: Endothelial cell gene expression in response to injury. FASEB J 1993;7:523-532.
36. Wuthrich R: Intercellular adhesion molecules and vascular cell adhesion molecule-1 and the kidney. J Am Soc Nephrol 1992;3:1201-1211.
37. Brady H: Leukocyte adhesion molecules and kidney diseases. Kidney Int 1994;45:1285-1300.
38. Hill P, Main IW, Atkins RC: ICAM-1 and VCAM-1 in human renal allograft rejection. Kidney Int 1995;47:1383-1391.
39. Dougherty G, Murdoch S, Hogg N: The function of human intercellular adhesion molecule-1 (ICAM-1) in the generation of an immune response. Eur J Immunol 1988;18:35-39.
40. Kelly KJ, Williams W, Colvin RB, Bonventre JV: Antibody to intracellular adhesion molecule 1 protects the kidney against ischemic injury. Proc Natl Acad Sci USA 1994;91:812-816.
41. Rabb H, Mendiola CC, Dietz J, Saba, SR, Issekutz TB, Abanilla F, Bonventre JV, Ramirez G: Role of CD11a and CD11b in ischemic acute renal failure in rats. Am J Physiol 1994; 267:F1052-F1058.
42. Kelly KJ, Williams WW, Colvin RB, Meehan SM, Springer TA, Gutierrez-Ramos JC, Bonventre JV: Intercellular adhesion molecule-1-deficient mice are protected against ischemic renal injury. J Clin Invest 1996;97:1056-1063.
43. Zamecnik PC, Stephenson ML: Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 1978;75:280-2284.
44. Wagner R: Gene inhibition using antisense oligodeoxynucleotides. Nature 1994;372:333-335.
45. Crooke S: Progress toward oligonucleotide therapeutics: Pharmacodynamic properties. FASEB J 1993;7:533-539.
46. Beltinger C, Saragovi HU, Smith RM, LeSauteur L, Shah N, DeDionisio L, Christensen L, Raible A, Jarett L, Gewritz AM: Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J Clin Invest 1995;95:1814-1823.
47. Lewis J, Lin KY, Kothavale A, Flanagan WM, Matteucci MD, et al: A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA. Proc Natl Acad Sci USA 1996;93:3176-3181.
48. 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J Pharmacol Exp Ther 1993;267:1181-1190.
49. Diasio RB, Zhang R: Pharmacology of therapeutic oligonucleotides. Antisense Nucleic Acid Drug Dev 1997;7:239-243.
50. Oberbauer R, Schreiner GF, Meyer TW: Renal uptake of an 18-mer phosphorothioate oligonucleotide. Kidney Int 1995;48:1226-1232.
51. Rappaport J, Hanss B, Kopp JB, Copeland TD, Bruggeman LA, Coffman TM, Klotman PE: Transport of phosphorothioate oligonucleotides in kidney: Implications for molecular therapy. Kidney Int 1995;47:1462-1469.
52. Krieg AM, Stein CA: Phosphorothioate oligodeoxynucleotides: Antisense or anti-protein. Antisense Res Dev 1995;5:241.
53. Stein CA: Controversies in the cellular pharmacology of oligodeoxynucleotides. Antisense Nucleic Acid Drug Dev 1997;7:207-209.
54. Burgess T, Fisher EF, Ross SL, Bready JV, Qian Y-X, Bayewitch LA, Cohen, AM, Herrera CJ, Hu SSF, Kramer TB, Lott FD, Martin FH, Pierce GF, Simonet L, Farrel CL: The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc Natl Acad Sci USA 1995;92:4051-4055.
55. Stein CA, Cleary AM, Yakubov L, Lederman S: Phosphorothioate oligodeoxynucleotides bind to the third variable loop domain (v3) of human immunodeficiency virus type gp120. Antisense Res Dev 1993;3:19-31.
56. Benimetskaya L, Loike JD, Khaled Z, et al: Mac-1 (CD11b/CD18) is an oligodeoxynucleotide-binding protein. Nat Med 1997;3:414-420.
57. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky J, Klinman DM: CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995;374:546-549.
58. Stein C: Does antisense exist? Nat Med 1995;1: 1119-1121.
59. Crooke S: An overview of progress in antisense therapeutics. Antisense Nucleic Acid Drug Dev 1998;8:115-122.
60. Bennett CF: Antisense oligonucleotides: Is the glass half full or half empty? Biochem Pharmacol 1998;55:9-19.
61. Dean Nag RH: Identification and characterization of second-generation antisense oligonucleotides. Antisense Nucleic Acid Drug Dev 1997;7:229-233.
62. Agrawal S, Jiang Z, Zhao Q, Haw D, Cai Q, Roskey A, Channavajjala L, Saxinger C, Zhang R: Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: In vitro and in vivo studies. Proc Natl Acad Sci USA 1997;94:2620-2625.
63. Shoskes D, Halloran, PF: Delayed graft function in renal transplantation: Etiology, management and long-term significance. J Urol 1996; 155:1831-1840.
64. Azuma H, Nadeau K, Takada M, Tilney NL: Initial ischemia/reperfusion injury influences late functional and structural changes in the kidney. Transplant Proc 1997;29:1528-1529.
65. Tullius SG, Heemann UW, Hanckock WW, Azuma H, Tilney NL: Long-term kidney isografts develop functional and morphologic changes that mimic those of chronic allograft rejection. Ann Surg 1994;220:425-435.
66. Kelly KJ, Williams W, Colvin RB, Bonventre JV: Antibody to intercellular adhesion molecule 1 protects the kidney against ischemic injury. Proc Natl Acad Sci USA 1994;91:812-816.
67. Butler M, Stecker K, Bennett CF: Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues. Lab Invest 1997;77:379-388.
68. Carome M, Kang Y-H, Bohen EM, Nicholson DE, Carr FE, Kiandoli FE, Brummel SE, Yuan CM: Distribution of the cellular uptake of phosphorothioate oligodeoxynucleotides in the rat kidney in vivo. Nephron 1997;75:82-87.